These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21497705)

  • 61. The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?
    Doggrell SA
    Expert Opin Pharmacother; 2012 Jul; 13(10):1469-80. PubMed ID: 22725704
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Lipid therapy in daily routine].
    Sonntag F; Schaefer JR; Gitt AK; Weizel A; Jannowitz C; Karmann B; Pittrow D; Bestehorn K
    Dtsch Med Wochenschr; 2012 Oct; 137(40):2047-52. PubMed ID: 23023622
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration.
    Araujo DB; Bertolami MC; Ferreira WP; Abdalla DS; Faludi AA; Nakamura Y; Bricharello LP
    J Cardiovasc Pharmacol; 2010 Jan; 55(1):1-5. PubMed ID: 19770669
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Enhanced hypercholesterolemia therapy: the ezetimibe/simvastatin tablet.
    Cole P; Rabasseda X
    Drugs Today (Barc); 2005 May; 41(5):317-27. PubMed ID: 16082429
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
    Cannon CP; Giugliano RP; Blazing MA; Harrington RA; Peterson JL; Sisk CM; Strony J; Musliner TA; McCabe CH; Veltri E; Braunwald E; Califf RM;
    Am Heart J; 2008 Nov; 156(5):826-32. PubMed ID: 19061694
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.
    Leiter LA; Betteridge DJ; Farnier M; Guyton JR; Lin J; Shah A; Johnson-Levonas AO; Brudi P
    Diabetes Obes Metab; 2011 Jul; 13(7):615-28. PubMed ID: 21332628
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
    Sharp Collaborative Group
    Am Heart J; 2010 Nov; 160(5):785-794.e10. PubMed ID: 21095263
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Drug of the month. Ezetimibe/simvastatin tablet (Inegy)].
    Scheen AJ; Radermecker RP
    Rev Med Liege; 2007 Sep; 62(9):585-90. PubMed ID: 17966796
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Ezetimibe in clinical practice: from laboratory investigations to the IMPROVE-IT trial results].
    Borghi C; Filardi PP
    G Ital Cardiol (Rome); 2015; 16(7-8 Suppl 1):3S-14S. PubMed ID: 26442834
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [LDL cholesterol lowering therapy: no target value but personalised treatment].
    Simoons ML; Deckers JW
    Ned Tijdschr Geneeskd; 2015; 159():A8770. PubMed ID: 25923500
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Low persistence of simvastatin and ezetimibe fixed combination in the lipid lowering therapy].
    Simonyi G; Ferenci T
    Orv Hetil; 2015 Jan; 156(4):141-5. PubMed ID: 25597318
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination.
    Neal RC; Jones PH
    Vasc Health Risk Manag; 2006; 2(1):31-8. PubMed ID: 17319467
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS.
    Howard WJ
    Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):295-300. PubMed ID: 20556890
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial.
    Holme I; Boman K; Brudi P; Egstrup K; Gohlke-Baerwolf C; Kesäniemi YA; Malbecq W; Rossebø AB; Wachtell K; Willenheimer R; Pedersen TR
    Am J Cardiol; 2010 Jun; 105(12):1802-8. PubMed ID: 20538134
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ezetimibe/Simvastatin: a review of its use in the management of hypercholesterolemia.
    Murdoch D; Scott LJ
    Am J Cardiovasc Drugs; 2004; 4(6):405-22. PubMed ID: 15554726
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (studie IMPROVE-IT)].
    Špinar J; Špinarová L; Vítovec J
    Vnitr Lek; 2014 Dec; 60(12):1095-101. PubMed ID: 25692840
    [TBL] [Abstract][Full Text] [Related]  

  • 77. IMPROVE-IT: what have we learned?
    Banach M; Nikolic D; Rizzo M; Toth PP
    Curr Opin Cardiol; 2016 Jul; 31(4):426-33. PubMed ID: 27218683
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia.
    Davidson MH
    J Am Coll Cardiol; 2003 Jul; 42(2):398-9; author reply 399. PubMed ID: 12875794
    [No Abstract]   [Full Text] [Related]  

  • 79. The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic.
    Pearson GJ; Francis GA; Romney JS; Gilchrist DM; Opgenorth A; Gyenes GT
    Can J Cardiol; 2006 Sep; 22(11):939-45. PubMed ID: 16971979
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Homozygous hypercholesterolaemia and ezetimibe: a case report.
    Hendriksz CJ; Norbury G; Tabrah S; Taylor A; Humphries SE
    Acta Paediatr; 2004 Feb; 93(2):280-2. PubMed ID: 15046291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.